Initial results of AstraZeneca, Sputnik V 'mix & match' vaccine joint trials show no serious adverse events
News 24
Initial results of AstraZeneca, Sputnik V 'mix & match' vaccine joint trials show no serious adverse events
Russia's sovereign wealth fund on Friday announced initial safety results of the world's first study of a combination between the COVID-19 vaccine developed jointly with the University of Oxford and the first component of the Russian COVID-19 vaccine (Sputnik Light vaccine based on human adenovirus serotype 26) in the Republic of Azerbaijan. "The heterogeneous boosting approach ("vaccine cocktail") using human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component) was at the core of Sputnik V, the world's first registered vaccine against coronavirus," read a statement issued by the RDIF. The RDIF initiated the study in December 2020. The first partnership of this kind was concluded in December 2020 in the presence of Russian President Vladimir Putin.RDIF, The Gamaleya Center, AstraZeneca and R-Pharm signed a Memorandum of Intent aimed at cooperation in vaccine development. The RDIF was the first in the World to initiate such a study in December 2020."The first partnership of this kind was concluded in December 2020 in the presence of the President of Russia Vladimir Putin. RDIF, The Gamaleya Center, AstraZeneca and R-Pharm signed a Memorandum of Intent aimed at cooperation in vaccine development," said RDIF's statement.More Related News